(EMAILWIRE.COM, August 26, 2019 ) The Indian peptides market is projected to reach USD 883.0 Million by 2022 from USD 381.8 Million in 2016, at a CAGR of 15.0%.

The Indian heparin market to reach USD 170.2 Million in 2022 from USD 127.8 Million in 2016 and is expected to register a CAGR of 4.9%. Factors such as incidence of coagulation disorders and government support for pharmaceutical companies are contributing to the growth of this market.

Download the PDF Brochure@
https://www.marketsandmarkets.com/pdfdownload.asp?id=77044734

By type, insulin segment is expected to dominate the market in 2016

On the basis of type segmentation, The indian peptides market is classified into insulin, teriparatide, liraglutide, glucagaon, leuprolide acetate, octreotide acetate, calcitonin salmon, triptorelin, eptifibatide, glatimer acetate, bivalirudin, exenatide and other molecules.

The insulin segment is expected to dominate the Indian peptides market in 2016. Growing incidence and prevalence rate of diabetes in India and rising ageing population are the major driving factors for this segment.

By application, the diabetes segment is expected to dominate the market in 2016

Based on application, the indian peptides market is segmented into diabetes, infectious disease, cancer, cardiology, osteoporosis, gynecological application, and other applications.

Get the Sample Pages@
https://www.marketsandmarkets.com/requestsample.asp?id=77044734

In 2016, the diabetes segment is expected to account for the largest share of the Indian peptides market, by application. The growth in the segment can be primarily attributed to increasing incidence and prevalence of diabetes cases in the country.

Some of the major players operating in the Indian peptides market include Abbott Laboratories (U.S.), Sanofi S.A. (France), Eli Lilly and Company (U.S.), Cipla Limited (India), Biocon Limited (India), Intas Pharmaceuticals Ltd. (India), Sun Pharmaceutical Industries Ltd. (India), Cadila Pharmaceuticals (India), Lupin Limited (India), Emcure Pharmaceuticals Ltd. (India), Novartis International AG (Switzerland), Dr. Reddy’s Laboratories Limited (India), and Alkem Laboratories Limited (India).

By type, Enoxaparin sodium segment is expected to dominate the market in 2016

On the basis of type, the Indian heparin market is classified into enoxaparin sodium, heparin sodium, fondaparinux, and dalteparin sodium. In 2016, the enoxaparin sodium segment is expected to account for the largest share of the Indian heparin market, by type.

Enoxaparin sodium is available as an injectable that helps prevent blood clots in the leg veins of patients who have undergone hip/knee replacements or abdominal surgery. According to Human Pharmaceuticals at Boehringer Ingelheim, in India, approximately 231,132 venous thromboembolism (VTE) procedures occur annually; 53.6% of hospitalized Indian patients are at an increased risk of VTE.

Some of the major players operating in the Indian heparin market are Sanofi (France), Emcure Pharmaceutical Pvt. Ltd. (India), Cipla Ltd. (India), Bharat Serum (India), Pfizer Inc. (U.S.), Abbott Laboratories (U.S.), Lupin Ltd. (India), Dr. Reddy’s Laboratories (India), Intas Pharmaceuticals Ltd. (India), Samarth Life Sciences (India), Claris Lifesciences Limited (India), Gland Pharma Limited (India), Mylan Pharmaceutical (India), Torrent Pharmaceuticals (India), Micro Labs Ltd. (India), and VHB Lifesciences (India).

View Complete Press Release:-
https://www.marketsandmarkets.com/PressReleases/indian-peptides-heparin.asp